ChemGenex submits leukemia drug for FDA review

ChemGenex Pharmaceuticals filed for FDA approval of omacetaxine, a drug candidate for chronic myeloid leukemia. The Australian biotech firm hopes to market the small molecule therapy under the brand Omapro in the first half of next year.

View Full Article in:

Herald Sun (Melbourne, Australia) (tiered subscription model), The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Sr Statistician I (US/TB/00/0028/SL)
Santa Clara, CA
Food & Drug Associate
Washington, D.C., DC
Senior Manager, Gaps in Care
UAW Retiree Medical Benefits Trust
Detroit, MI
Compliance Director
Abbott Laboratories
Santa Clara, CA
Product Development Manager, Disposable Medical Products
ASAHI INTECC, Orange County CA R&D Center
Santa Ana, CA